$0.399000
-0.03-7.21%
Last update: 9:27 AM
15 minutes delayed
Comments
Loading...
BioVie
BIVINASDAQ
BioVie (NASDAQ:BIVI) Stock, Analyst Ratings, Price Targets, Forecasts
BioVie Inc has a consensus price target of $10.8 based on the ratings of 5 analysts. The high is $27 issued by B. Riley Securities on November 30, 2021. The low is $3 issued by ThinkEquity on July 1, 2024. The 3 most-recent analyst ratings were released by ThinkEquity, Oppenheimer, and Cantor Fitzgerald on July 1, 2024, November 30, 2023, and August 22, 2023, respectively. With an average price target of $6.33 between ThinkEquity, Oppenheimer, and Cantor Fitzgerald, there's an implied 1538.43% upside for BioVie Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
ThinkEquity
Oppenheimer
Cantor Fitzgerald
EF Hutton
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for BioVie
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | Buy Now | 676.1% | ThinkEquity | Ashok Kumar | → $3 | Initiates | → Buy | Get Alert |
| 11/30/2023 | Buy Now | 1193.49% | Oppenheimer | Jay Olson | $12 → $5 | Maintains | Outperform | Get Alert |
| 08/22/2023 | Buy Now | 2745.69% | Cantor Fitzgerald | Charles Duncan | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 07/18/2023 | Buy Now | 2745.69% | Cantor Fitzgerald | Charles Duncan | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | Buy Now | 2745.69% | Cantor Fitzgerald | Charles Duncan | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | Buy Now | 3004.38% | Oppenheimer | Jay Olson | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 02/14/2023 | Buy Now | 3004.38% | Oppenheimer | Jay Olson | → $12 | Reiterates | → Outperform | Get Alert |
| 09/28/2022 | Buy Now | 1969.59% | EF Hutton | Constantine Davides | $14 → $8 | Maintains | Buy | Get Alert |
| 07/22/2022 | Buy Now | 1710.89% | Cantor Fitzgerald | Charles Duncan | → $7 | Initiates | → Overweight | Get Alert |
| 03/17/2022 | Buy Now | 3521.78% | EF Hutton | Constantine Davides | $9 → $14 | Maintains | Buy | Get Alert |
| 03/15/2022 | Buy Now | 2228.29% | Oppenheimer | Jay Olson | → $9 | Initiates | → Outperform | Get Alert |
| 11/30/2021 | Buy Now | 6884.87% | B. Riley Securities | Mayank Mamtani | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for BioVie (BIVI) stock?
The latest price target for BioVie (NASDAQ:BIVI) was reported by ThinkEquity on July 1, 2024. The analyst firm set a price target for $3.00 expecting BIVI to rise to within 12 months (a possible 651.88% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioVie (BIVI)?
The latest analyst rating for BioVie (NASDAQ:BIVI) was provided by ThinkEquity, and BioVie initiated their buy rating.
When was the last upgrade for BioVie (BIVI)?
There is no last upgrade for BioVie
When was the last downgrade for BioVie (BIVI)?
There is no last downgrade for BioVie.
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
Is the Analyst Rating BioVie (BIVI) correct?
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a initiated with a price target of $0.00 to $3.00. The current price BioVie (BIVI) is trading at is $0.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.